Almirall Partnership Brings $6M Upfront, $470M Milestones to Eloxx Pharma Despite Widening Q1 Loss
Summary
Eloxx Pharmaceuticals reported a Q1 2026 net loss of $(3.75M), widening from $(1.71M) year-over-year, though diluted EPS loss improved to $(0.08). Crucially, the company announced an exclusive global license agreement with Almirall for ZKN-013, which includes a $6M upfront payment and eligibility for up to approximately $470M in development and commercial milestones plus royalties. This financial update follows recent corporate actions, including a reverse stock split and expanded share authorization, aimed at potential Nasdaq relisting and capital raising. For a company with a market cap under $1M, the $6M upfront payment is transformative, providing immediate capital and significantly de-risking its financial position and pipeline development. The potential $470M in milestones represents an enormous future value proposition. Investors will monitor the progress of the ZKN-013 program under Almirall and the company's other clinical advancements, as well as any further capital raising activities or progress towards Nasdaq relisting.
At the time of this announcement, ELOX was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $593.8K. The 52-week trading range was $0.00 to $13.90. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.